If I were right, what you referred to was DNDN, which offered Prostate Cancer Immunotherapy treatment. DNDN got 100% FDA advisory panel approval but FDA turned it down first, which cost me a lot for selling my 45K shares @ $4.55 (bought at $8.35). Within a couple months, the FDA finally approved it after so much pressure from the public due to some obvious corrupted FDA individuals' biased decision not to approve it. Then, DNDN jumped back up to > $45 per share.